Abstract |
In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath ( Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
|
Authors | Francesca R Mauro, Stefano Molica, Luca Laurenti, Agostino Cortelezzi, Angelo M Carella, Francesco Zaja, Annalisa Chiarenza, Francesco Angrilli, Francesco Nobile, Roberto Marasca, Caterina Musolino, Maura Brugiatelli, Alfonso Piciocchi, Marco Vignetti, Paola Fazi, Giuseppe Gentile, Maria S De Propris, Irene Della Starza, Marilisa Marinelli, Sabina Chiaretti, Ilaria Del Giudice, Mauro Nanni, Francesco Albano, Antonio Cuneo, Anna Guarini, Robin Foà, Gruppo Italiano Malattie EMatologiche dell’Adulto Working Party for Chronic Lymphoproliferative Disorders |
Journal | Leukemia research
(Leuk Res)
Vol. 38
Issue 2
Pg. 198-203
(Feb 2014)
ISSN: 1873-5835 [Electronic] England |
PMID | 24314589
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Alemtuzumab
- Vidarabine
- fludarabine
|
Topics |
- Adult
- Alemtuzumab
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy, mortality)
- Male
- Middle Aged
- Neoadjuvant Therapy
- Survival Analysis
- Treatment Outcome
- Vidarabine
(administration & dosage, adverse effects, analogs & derivatives)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|